News Headlines Article

FDA approves Genentech drug for stomach cancer
San Jose Business Journal

Genentech said Thursday the U.S. Food and Drug Administration approved Herceptin for use in treating stomach cancer. South San Francisco-based Genentech, a member of the Roche Group, said the drug is designed to be used in combination with chemotherapy. “Since Herceptin’s approval in HER2-positive advanced breast cancer more than a decade ago, we have continued to study how the HER2 pathway contributes to the growth and spread of other cancers, such as stomach cancer,” said Dr. Hal Barron, the company’s chief medical officer.